Back to Search
Start Over
Quantification of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) using amplicon-fusion-site polymerase chain reaction (AFS-PCR).
- Source :
-
Experimental hematology & oncology [Exp Hematol Oncol] 2012 Nov 09; Vol. 1 (1), pp. 33. Date of Electronic Publication: 2012 Nov 09. - Publication Year :
- 2012
-
Abstract
- The amplification of putative oncogenes is a common finding within the genome of various cancer types. Identification and further targeting of specific junction sites within the sequence of genomic amplicons (amplicon fusion sites, AFS) by PCR (AFS-PCR) is suitable for quantification of minimal residual disease (MRD). This approach has recently been developed and described for MYCN amplified neuroblastomas. To compare AFS-PCR directly to routinely used MRD diagnostic strategies, we mapped the amplified genomic regions (ampGR) of an iAMP21-amplicon in high resolution of a patient with acute lymphoblastic leukemia (ALL). Successfully, we established AFS-PCR covering junction sites between ampGR within the iAMP21-amplicon. Quantification of MRD by AFS-PCR was directly comparable to IgH/TCR based real time quantitative PCR and fluorescence activated cell sorting (FACS) analysis in consecutive bone marrow (BM) specimens. Our data give an additional proof of concept of AFS-PCR for quantification of MRD. The method could be taken into account for ALL patients with genomic amplifications as alternative MRD diagnostic, if no or qualitatively poor Ig/TCR-PCRs are available.
Details
- Language :
- English
- ISSN :
- 2162-3619
- Volume :
- 1
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Experimental hematology & oncology
- Publication Type :
- Academic Journal
- Accession number :
- 23210797
- Full Text :
- https://doi.org/10.1186/2162-3619-1-33